Lenzetto

Estradiol hemihydrate, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It relieves moderate to severe vasomotor symptoms associated with menopause and helps prevent osteoporosis in postmenopausal women.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto (estradiol hemihydrate) is used in hormone replacement therapy to address estrogen deficiency.

Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats. Postmenopausal osteoporosis: helps maintain bone mineral density and lowers fracture risk. Estrogen deficiency symptoms: alleviates mood swings, sleep disturbances and vaginal dryness.

Common Side Effects: - Skin irritation at the patch site: redness, itching or rash. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Breast tenderness: mild swelling or discomfort. - Bloating: abdominal fullness. - Mood changes: irritability or emotional lability.

Serious or Rare Side Effects: - Deep vein thrombosis: swelling, pain or redness in a limb. - Pulmonary embolism: sudden shortness of breath, chest pain. - Stroke: sudden weakness, speech difficulty. - Myocardial infarction: chest discomfort, radiating pain. - Gallbladder disease: abdominal pain, jaundice. - Severe allergic reaction: hives, swelling, difficulty breathing.

Before initiating therapy, consider the following precautions.

Assess cardiovascular risk: evaluate history of thromboembolic events. Screen for estrogen‑dependent neoplasia: avoid in known breast or endometrial cancer. Monitor liver function: adjust use in hepatic impairment. Consider bone health: combine with calcium and vitamin D as needed. Avoid use during pregnancy: contraindicated in pregnant women. Store at room temperature: keep patch in original packaging, protect from moisture and direct sunlight.

Estradiol hemihydrate may interact with several medicines.

Major Interactions (Avoid): - Combined hormonal contraceptives: increased risk of thromboembolism. - Anticoagulants (e.g., warfarin): may reduce anticoagulant effect, monitor INR. - CYP3A4 inducers (rifampin, carbamazepine): may lower estradiol plasma levels.

Moderate Interactions (Monitor Closely): - Tamoxifen: antagonistic effect on estrogen receptors, may reduce efficacy. - Antihypertensives: potential fluid retention may alter blood pressure control. - Lithium: possible increase in serum lithium levels, monitor for toxicity.